Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEF0117 for Cannabis Use Disorder
NCT03717272Phase 2Completed
- Sponsor
- Aelis Farma
- Start
- Oct 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aef0117 in cannabis use disorder (CUD) (2 arms), sponsored by Aelis Farma. Primary endpoint: Peak Subjective Effects of Cannabis (Good Drug Effect Subscale). Started Oct 2018; status: completed.
02
Drugs
aef0117
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03717272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717272.